The estimated Net Worth of Sergio Traversa is at least $2.4 Million dollars as of 9 September 2024. Mr. Traversa owns over 140,000 units of Relmada Therapeutics Inc stock worth over $1,159,752 and over the last 6 years he sold RLMD stock worth over $0. In addition, he makes $1,236,360 as Chief Executive Officer und Director at Relmada Therapeutics Inc.
Sergio has made over 13 trades of the Relmada Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 140,000 units of RLMD stock worth $394,800 on 9 September 2024.
The largest trade he's ever made was buying 140,000 units of Relmada Therapeutics Inc stock on 9 September 2024 worth over $394,800. On average, Sergio trades about 18,263 units every 62 days since 2018. As of 9 September 2024 he still owns at least 384,024 units of Relmada Therapeutics Inc stock.
You can see the complete history of Mr. Traversa stock trades at the bottom of the page.
Sergio C. Traversa serves as Chief Executive Officer, Director of the Company since April 2012. Previously, from January 2010 to April 2012 he was the CEO of Medeor Inc., a spinoff pharmaceutical company from Cornell University. From January 2008 to January 2010, Dr. Traversa was a partner at Ardana Capital. Dr. Traversa has over thirty years of experience in the healthcare sector in the United States and Europe, ranging from management positions in the pharmaceutical industry to investing and strategic advisory roles. He has held financial analyst, portfolio management and strategic advisory positions at large U.S. investment firms specializing in healthcare, including Mehta, Isaly and Mehta Partners, ING Barings, Merlin BioMed and Rx Capital. Dr. Traversa was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. In Europe, he held the position of Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson & Johnson. Prior to Therakos, Dr. Traversa was at Eli Lilly, where he served as Marketing Manager of the Hospital Business Unit. He was also a member of the CNS (Central Nervous System) team at Eli Lilly, where he participated in the launch of Prozac and the early development of Zyprexa and Cymbalta. Dr. Traversa started his career as a sales representative at Farmitalia Carlo Erba, the largest pharmaceutical company in Italy, now part of Pfizer. Mr. Traversa was also a board member of Actinium Pharmaceuticals, Inc. Dr. Traversa holds a Laurea degree in Pharmacy from the University of Turin (Italy) and an MBA in Finance and International Business from the New York University Leonard Stern School of Business. As Chief Executive Officer of the Company, Dr. Traversa is the most senior executive of the Company and as such provides our Board of Directors with the greatest insight into the Company’s business and the challenges and material risks it faces.
As the Chief Executive Officer und Director of Relmada Therapeutics Inc, the total compensation of Sergio Traversa at Relmada Therapeutics Inc is $1,236,360. There are no executives at Relmada Therapeutics Inc getting paid more.
Sergio Traversa is 59, he's been the Chief Executive Officer und Director of Relmada Therapeutics Inc since 2019. There are 8 older and 6 younger executives at Relmada Therapeutics Inc. The oldest executive at Relmada Therapeutics Inc is Charles Casamento, 75, who is the Independent Chairman of the Board.
Sergio's mailing address filed with the SEC is C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES, FL, 33134.
Over the last 6 years, insiders at Relmada Therapeutics Inc have traded over $1,379,052 worth of Relmada Therapeutics Inc stock and bought 574,305 units worth $1,722,071 . The most active insiders traders include Sergio Traversa, Charles J Casamento und Paul Edward Kelly. On average, Relmada Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $54,221. The most recent stock trade was executed by Sergio Traversa on 9 September 2024, trading 140,000 units of RLMD stock currently worth $394,800.
relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and
Relmada Therapeutics Inc executives and other stock owners filed with the SEC include: